From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

RFP – Nuclear Medical Countermeasure Development

by Global Biodefense Staff
August 26, 2014
Biodefense Vaccine Development

Credit: Shutterstock, modified by Global Biodefense

The National Institute of Allergy and Infectious Diseases (NIAID) Division of Allergy, Immunology and Transplantation (DAIT) has a requirement for developing products for treatment of radiation injuries from exposures due to a nuclear and radiological attacks.

NIAID is soliciting proposals for a contract entitled “Radiation/Nuclear Medical Countermeasure Product Development Support Services” to advance the development of candidate medical countermeasures (MCMs).

Research and development studies supported by this RFP will advance candidate MCMs to a stage where products are eligible for advanced product development by the Biomedical Advanced Research and Development Authority (BARDA) or acquisition under the Project BioShield Act of 2004.

It is anticipated that one Indefinite Delivery Indefinite Quantity type contract will be awarded for a 5-year period of performance beginning on or about August 1, 2015.

The Task Areas will include:

  • Administrative and Technical Support
  • Animal Model Development and Efficacy Testing of Candidate Medical Countermeasures
  • Nonclinical Studies in Support of IND/NDA/BLA
  • Phase I Clinical Studies
  • Chemistry, Manufacturing and Control Support Services

The first Task Area is anticipated to encompass a cost-reimbursement, term (level of effort) Task Order and the others completion type cost reimbursement Task Orders.  Options may be used to extend the period of performance of some Task Orders.

Further details are available under Solicitation Number: RFP-NIAID-DAIT-NIHAI2014005. The response deadline is December 1, 2014.

From Our Partners
Tags: Animal ModelsASPRBARDAHHSNIAIDRadiation

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC